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Introduction
In vitro and in vivo studies emphasize that insulin-like
growth factor binding protein-4 (IGFBP-4) may play an 
important role in modulating IGF actions in bone. IGFBP-4 is
the major IGFBP produced by human osteoblasts and has
been shown to be a potent inhibitor of IGF-stimulated cell
proliferation (1,2). This effect is further modified by IGFBP-4
protease under variety of experimental conditions (3).
Parathyroid hormone (PTH), 1, 25-hydroxy(OH)vitamin D,
IGF-I, IGF-II and transforming growth factor (TGF)-β
are known regulators of IGFBP-4 production in vitro in 
human bone cells (4-7). However, little is known about the
physiological regulation of circulating IGFBP-4 in humans. It
was found that plasma IGFBP-4 levels correlated with bone
mineral density in growth hormone (GH)-deficient adults (8).
The increased circulating IGFBP-4 levels are found in elderly
women with hip and spine fractures. Increase in IGFBP-4
was correlated with increased PTH in these women (9). This
observation supported the role of PTH in the regulation of
IGFBP-4. On the other hand, in subjects with primary 
hyperparathyroidism due to adenoma or hyperplasia, IGFBP-4
levels were found to be subnormal (10). Thus, human 
studies are inconclusive regarding the role of PTH in 
regulation of circulating IGFBP-4. To further investigate the
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measure serum IGFBP-4 levels in situations, where 
hyperparathyroidism is more prominent and reversible. 
Vitamin D deficiency rickets is a perfect condition to test
this hypothesis since secondary hyperparathyroidism is 
severe and is corrected rapidly after initiation of Vitamin D
therapy. Thus, to investigate the role of PTH in the regulation
of IGFBP-4 levels, we prospectively measured serum IGF-I,
IGFBP-3, IGFBP-4 and PTH concentrations in infants with
nutritional rickets before and after treatment. 
Methods
Patients with rickets were recruited from the outpatient
clinics of Pediatric Hospitals after obtaining informed 
consent from the parents/guardian of each child. Diagnosis
of rickets was established according to clinical, biochemical
and radiological findings. Children who had a history of 
prematurity, renal, liver or intestinal disease or evidence of
any of these disorders on physical examination or laboratory
testing were excluded. Altogether, 22 infants with a mean
age of 1.3±1.6 years were included in the study. Blood
samples were obtained before and 3 months after 
treatment of rickets with vitamin D. The treatment was 
achieved by giving a single oral dose of 300 000 U of 
Vitamin D (stoss-therapy). Serum from the blood samples
was separated within 2 h of the collection and was stored
at -20 °C until assayed. Serum calcium (Ca), phosphate (P),
and total alkaline phosphatase (ALP) levels were determined
by automatic analyzer. Serum intact PTH was measured by
a two-site immunoradiometric assay (Allegro). Serum 
25-(OH)Vitamin D levels were measured by chemiluminescen-
ce using Nichols Advantage competitive binding assay (San 
Juan Capistrano, California, USA). Serum IGF-I was 
determined by IRMA (DSL-5600 active, Diagnostics System
laboratories, Webster, TX, USA) after separation of IGFs
from IGFBPs by acid-ethanol extraction and neutralization
as described previously (11). Including the extraction step,
the intraassay coefficient of variation (CV) was 5%, 
whereas the interassay CV was 12 %. Serum concentrations
of IGFBP-3 were also measured by IRMA (DSL-6600) (11).
Intraassay CV was 6% and interassay CV was 16%. 
Serum IGFBP-4 was measured by an ELISA (DSL active
IGFBP-4) assay according to the manufacturer’s directions.
For all measurements, interassay variability was less than
9% and intraassay variability was less than 7%. All blood
samples were measured in duplicate.
Statistics
Paired t-test was used to evaluate the differences in 
parameters examined before and after treatment with 
Vitamin D. Simple regression was used to analyze the 
relationships between the study parameters.
Results
The mean (±SD) age of the patients was 1.3±1.6 
(range 0.2 -3.0) years at the beginning of the study. Table 1
summarizes the findings on biochemical indices of rickets
and IGF-I, IGFBP-3 and IGFBP-4 levels before and after 
treatment with vitamin D. These findings show that the 
patients had severe vitamin D deficiency with low blood 
levels of Ca and P, and very high levels of ALP and PTH.
These values were almost completely normalized 3 months
after treatment. Serum IGF-I and IGFBP-3 levels both 
increased after treatment for rickets, while serum IGFBP-4
levels did not change significantly (18.8±8.0 vs. 21.5±4.8 ng/ml). 
Correlation analyses demonstrated no relationship 
between PTH and IGF-I, IGFBP-3 or IGFBP-4 levels. Significant
correlations were detected between PTH and ALP (r=0.53,
p<0.05), and also between IGF-I and IGFBP-3 (r=0.46, 
p<0.05) before treatment, and before and after treatment
combined. 
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Table 1. Serum calcium, phosphorus, alkaline phosphatase, PTH, 25-OH vitamin D, IGF-I, IGFBP-3 and IGFBP-4 levels before and after treatment in
patients with rickets
Before treatment After treatment P
Calcium (mg/dL) 6.6±1.4 9.5±1.6 <0.001
Phosphorus (mg/dL) 3.9±1.4 5.4±0.8 <0.01
Alkaline phosphatase (IU/mL) 2590±2630 1072±776 <0.05
PTH (ng/dL) 407±248 27.4±20.8 <0.001
25-(OH) vitamin D (ng/mL) 7.75±2.49 18.12±3.98 <0.001
IGF-I (ng/mL) 13.5±12.2 23.7±14.2 <0.001
IGFBP-3 (ng/mL) 1108±544 1652±424 <0.001
IGFBP-4 (ng/mL) 18.8±8.0 21.5±4.8 NS
PTH: parathyroid hormone
NS: nonsignificant Discussion
The results of this study demonstrate that circulating
IGFBP-4 levels are not influenced by secondary 
hyperparathyroidism in vitamin D deficiency rickets since
IGFBP-4 levels did not change after normalization of PTH
with vitamin D treatment. This observation is contradictory
to the data obtained in in vitro studies suggesting regulation
of IGFBP-4 by PTH and/or Vitamin D.
In vitro studies demonstrated a stimulatory effect of
PTH on IGFBP-4 production. Treatment of SaOS-2 cells
with PTH for 3 hours caused a 3.3-fold increase in IGFBP-4
mRNA levels, which was determined by reverse transcription-
polymerase chain reaction (7). 1.25 (OH)2 D3 increases the
secretion of IGFBP-4 by human osteoblast-like cells (5). 
Data regarding regulation of serum IGFBP-4 in humans are
scarce. Using Western ligand blot analysis, Rosen et al (9)
showed that serum IGFBP-4 levels are higher in elderly 
women with hip fractures and elevated PTH levels compared
with age-matched controls. It was speculated that an 
increased local production of IGFBP-4 would inhibit the IGF
stimulatory actions on bone synthesis potentiating the 
effect of PTH on bone resorption in these patients. 
However, in a recent study, serum IGFBP-4 levels were 
positively correlated with only radial bone mineral density
(BMD), but not with lumbar or femoral BMD and vertebral
fractures (12). 
Honda et al (13) also found a weak correlation (r=0.26)
between serum IGFBP-4 and PTH in healthy adults and 
in elderly individuals. They suggested that secondary 
hyperparathyroidism, which occurs as a consequence of
age, could induce the inhibition of osteoblast proliferation
by production of IGFBP-4 in the locale of bone-remodeling
sites. Although much remains to be learned, our observation
of no correlation in a more severe secondary hyperparathyroid
state suggests that this conclusion is not valid. Consistent
with our findings, Jehle et al (14), using Western blot 
found that IGFBP-4 levels in patients with primary
hyperparathyroidism are comparable to those in controls.
Similarly, Van Doorn et al (10), using RIA, found subnormal
IGFBP-4 levels in subjects with primary hyperparathyroidism
due to adenoma or hyperplasia, supporting what we 
observed in a secondary hyperparathyroid state in the 
present study.
Unlike previous cross-sectional studies, the present
study is the first one to prospectively analyze serum IGFBP-4
levels in a high PTH state and after PTH levels have been
decreased. We have seen no significant change in IGFBP-4
levels after the dramatic reduction of PTH in the subjects,
while a slight increase was observed in IGF-I and IGFBP-3
levels. It is likely that the observed correlation between
IGFBP-4 and PTH in the previous cross-sectional studies
was influenced by some covariants ,such as age. In fact, 
serum IGFBP-4 levels correlated more strongly with age
than with PTH levels (13).
The increase in both IGF-I and IGFBP-3 levels after the
treatment of rickets may be due to a direct stimulatory 
effect of vitamin D and/or to improvement of nutritional 
status. However, none of the patients in this series were in
a malnourished state. Similar to our findings, increased 
consumption of milk in elderly subjects for 3 months 
resulted in a decline in both PTH and ALP by 9%, in a 
significant rise in IGF-I by 10% and in a nonsignificant fall in
IGFBP-4 by 1.9% (15). This observation is consistent with
the findings in our study, where IGFBP-4 levels did not
change significantly despite dramatic decline in PTH and
ALP levels. 
We conclude that circulating IGFBP-4 levels in children
with rickets are not regulated by PTH or vitamin D, since
the levels did not undergo significant change despite a 
20-fold decrease in PTH levels after treatment with vitamin
D. This finding is not in line with the data obtained from 
elderly persons and from in in vitro studies. It is likely that
the paracrine and endocrine regulators of IGFBP-4 are 
different.
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